Skip to content
CheckOrphan
  • Home
  • About Us
  • Log In
  • News
    • All News
    • Finance
    • Treatment
    • People
  • Videos
  • Treatments
  • Clinical Trials
  • Access Programs
    • About Access Programs
  • Diseases
  • Events
  • Networks
  • Research
Main Menu

Subscribe for Free Newsletter

Email *

Type *

Warning: foreach() argument must be of type array|object, null given in /var/www/wordpress/wp-content/themes/awaken-child/single-newsletter.php on line 54

* Required Field
Email Marketing Services by Benchmark

Generate RSS

  1. Home
  2. /
  3. Treatment
  4. /
  5. amifampridine phosphate

amifampridine phosphate

March 20, 2017
amifampridine phosphate
Trade Name
Orphan Indication Myasthenia gravis Myasthenia gravis
USA Market Approval USA
USA Designation Date 2016-08-31 00:00:00
Sponsor Catalyst Pharmaceuticals, Inc.;355 Alhambra Circle, Suite 1250;Coral Gables, Florida, 33134
Learn more about:
Myasthenia gravis

Free Newsletter

Related Treatment

  • Mutated form of human acetylcholine receptor a1 extracellular domain s
  • Immune globulin (human)
  • Fusion proteins composed by a genetically modified cholera toxin subun
  • Eculizumab
  • Recombinant Human Alpha-Fetoprotein (rhAFP)
More Treatment
pw

About CheckOrphan

CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected diseases. CheckOrphan offers users an interactive and dynamic platform for all these diseases. This strategy allows visitors to be updated daily on all the latest news and interact with people internationally. This is essential, because due to the nature of these diseases, there is not a large concentration of individuals within any given proximity.
Click here to know more About Us

Your email is important to us

Each email is sent to a CheckOrphan staff member and will be answered. We only use a contact form to avoid spam.

    Copyright © 2023 CheckOrphan.
    Developed by: Gonza.io logo Developed by: WebOptimalSolutions Powered by: Cloudscale logo